Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00714246 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Bortezomib
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

Milton S. Hershey Medical Center

Collaborators

[object Object]